JPWO2019198051A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019198051A5 JPWO2019198051A5 JP2021504593A JP2021504593A JPWO2019198051A5 JP WO2019198051 A5 JPWO2019198051 A5 JP WO2019198051A5 JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021504593 A JP2021504593 A JP 2021504593A JP WO2019198051 A5 JPWO2019198051 A5 JP WO2019198051A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- binding protein
- seq
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025417 antigen binding proteins Human genes 0.000 claims 55
- 108091000829 antigen binding proteins Proteins 0.000 claims 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims 52
- 239000000203 mixture Substances 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 13
- 102000038129 antigens Human genes 0.000 claims 13
- 108091007172 antigens Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102100015541 FCGR3A Human genes 0.000 claims 12
- 101710044656 FCGR3A Proteins 0.000 claims 12
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 11
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 11
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 11
- 108010031324 daratumumab Proteins 0.000 claims 8
- 229960002204 daratumumab Drugs 0.000 claims 8
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 201000009251 multiple myeloma Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100003279 CD38 Human genes 0.000 claims 1
- 101700044948 CD38 Proteins 0.000 claims 1
- 102100014838 FCGRT Human genes 0.000 claims 1
- 230000035693 Fab Effects 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 210000004693 NK cell Anatomy 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167384.9 | 2018-04-13 | ||
| EP18167385 | 2018-04-13 | ||
| EP18167385.6 | 2018-04-13 | ||
| EP18167384 | 2018-04-13 | ||
| EP18190662.9 | 2018-08-24 | ||
| EP18190662 | 2018-08-24 | ||
| EP18190661.1 | 2018-08-24 | ||
| EP18190661 | 2018-08-24 | ||
| PCT/IB2019/053040 WO2019198051A2 (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521275A JP2021521275A (ja) | 2021-08-26 |
| JPWO2019198051A5 true JPWO2019198051A5 (de) | 2022-04-20 |
Family
ID=66625219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504593A Pending JP2021521275A (ja) | 2018-04-13 | 2019-04-12 | Ｎｋ細胞結合抗体融合構築物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11001633B2 (de) |
| EP (1) | EP3774914A2 (de) |
| JP (1) | JP2021521275A (de) |
| KR (1) | KR20200143436A (de) |
| CN (3) | CN113880952A (de) |
| AU (1) | AU2019252970A1 (de) |
| BR (1) | BR112020020828A2 (de) |
| CA (1) | CA3095373A1 (de) |
| CL (2) | CL2020002625A1 (de) |
| CO (1) | CO2020014167A2 (de) |
| CR (1) | CR20200549A (de) |
| IL (1) | IL277925A (de) |
| MA (1) | MA52227A (de) |
| MX (1) | MX2020010728A (de) |
| PE (1) | PE20201346A1 (de) |
| PH (1) | PH12020551664A1 (de) |
| RU (1) | RU2022105827A (de) |
| SG (1) | SG11202010064QA (de) |
| TW (1) | TW202012441A (de) |
| WO (1) | WO2019198051A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4034245A1 (de) * | 2019-09-25 | 2022-08-03 | Universität Stuttgart | Dreiwertige bindungsmoleküle |
| US20230227559A1 (en) * | 2019-12-10 | 2023-07-20 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
| AU2020414409A1 (en) | 2019-12-27 | 2022-06-16 | Affimed Gmbh | Method for the production of bispecific FcyRIIl x CD30 antibody construct |
| WO2022074206A1 (en) | 2020-10-08 | 2022-04-14 | Affimed Gmbh | Trispecific binders |
| JP2023548538A (ja) * | 2020-11-08 | 2023-11-17 | シージェン インコーポレイテッド | 併用療法 |
| MX2023006573A (es) * | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
| EP4330436A1 (de) | 2021-04-30 | 2024-03-06 | Genentech, Inc. | Therapeutische und diagnostische verfahren und zusammensetzungen gegen krebs |
| AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
| CN116574190A (zh) * | 2021-07-30 | 2023-08-11 | 启愈生物技术(上海)有限公司 | 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用 |
| CN113929785B (zh) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用 |
| WO2023049909A1 (en) * | 2021-09-24 | 2023-03-30 | Synergy Imt, Inc. | Composition of recombinant antigen binding molecules and method of making and using thereof |
| CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| CN114349869B (zh) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | 一种双特异性的nk细胞激动剂及制备方法和应用 |
| WO2024027828A1 (en) * | 2022-08-05 | 2024-02-08 | Chimagen Biosciences, Ltd | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen |
| WO2024059677A2 (en) * | 2022-09-14 | 2024-03-21 | Ibio, Inc. | Pd-1 agonist antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP2004533997A (ja) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス，インコーポレイティド | Ｂｃｍａ及びｔａｃｉの両者を結合する抗体 |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| PL2361936T3 (pl) * | 2010-02-25 | 2016-10-31 | Cząsteczka wiążąca antygen i jej zastosowania | |
| ES2953190T3 (es) | 2011-05-27 | 2023-11-08 | Glaxo Group Ltd | Proteínas de unión a BCMA (CD269/TNFRSF17) |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US9676857B2 (en) | 2012-03-16 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble engineered monomeric Fc |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| EP2914628A1 (de) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | Antikörper mit bindung von cd269 (bcma) zur behandlung von plasmazellenkrankheiten wie multiplem myelom und autoimmunerkrankungen |
| EP2953974B1 (de) | 2013-02-05 | 2017-12-20 | EngMab Sàrl | Bispezifische antikörper gegen cd3 und bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| CN105189557A (zh) * | 2013-03-15 | 2015-12-23 | 默克专利有限公司 | 四价双特异性抗体 |
| CA2936785A1 (en) * | 2014-01-15 | 2015-07-23 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| KR20230149328A (ko) * | 2014-12-22 | 2023-10-26 | 시스트이뮨, 인코포레이티드 | 이중특이적 4가 항체 및 이의 제조 및 사용방법 |
| JP2018503399A (ja) * | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| EP3091031A1 (de) * | 2015-05-04 | 2016-11-09 | Affimed GmbH | Kombination eines bispezifischen antikörpers mit einem immunmodulierenden molekül zur behandlung eines tumors |
| AU2016257334B2 (en) * | 2015-05-04 | 2021-08-12 | Affimed Gmbh | Combination of a CD30xCD16 antibody with a PD-1 antagonist for therapy |
| WO2016207278A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| HUE050556T2 (hu) * | 2015-08-17 | 2020-12-28 | Janssen Pharmaceutica Nv | Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai |
| EP3156417A1 (de) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalente fv antikörper |
| CN105367660B (zh) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | 一种抗cd16a抗原和抗muc1抗原的双特异性抗体 |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| DK3589655T3 (da) * | 2017-02-28 | 2022-11-28 | Affimed Gmbh | Tandem diabody til cd16a målrettet nk-celle optagelse |
-
2019
- 2019-04-12 KR KR1020207032435A patent/KR20200143436A/ko unknown
- 2019-04-12 EP EP19725409.7A patent/EP3774914A2/de active Pending
- 2019-04-12 CN CN202111125559.3A patent/CN113880952A/zh active Pending
- 2019-04-12 WO PCT/IB2019/053040 patent/WO2019198051A2/en active Application Filing
- 2019-04-12 CA CA3095373A patent/CA3095373A1/en active Pending
- 2019-04-12 CN CN201980033176.8A patent/CN112119097B/zh active Active
- 2019-04-12 PE PE2020001584A patent/PE20201346A1/es unknown
- 2019-04-12 MA MA052227A patent/MA52227A/fr unknown
- 2019-04-12 BR BR112020020828-0A patent/BR112020020828A2/pt unknown
- 2019-04-12 RU RU2022105827A patent/RU2022105827A/ru unknown
- 2019-04-12 MX MX2020010728A patent/MX2020010728A/es unknown
- 2019-04-12 CN CN202111125475.XA patent/CN113817066A/zh active Pending
- 2019-04-12 SG SG11202010064QA patent/SG11202010064QA/en unknown
- 2019-04-12 JP JP2021504593A patent/JP2021521275A/ja active Pending
- 2019-04-12 AU AU2019252970A patent/AU2019252970A1/en active Pending
- 2019-04-12 CR CR20200549A patent/CR20200549A/es unknown
- 2019-04-15 TW TW108113068A patent/TW202012441A/zh unknown
- 2019-12-13 US US16/714,396 patent/US11001633B2/en active Active
-
2020
- 2020-10-08 PH PH12020551664A patent/PH12020551664A1/en unknown
- 2020-10-09 CL CL2020002625A patent/CL2020002625A1/es unknown
- 2020-10-11 IL IL277925A patent/IL277925A/en unknown
- 2020-11-12 CO CONC2020/0014167A patent/CO2020014167A2/es unknown
-
2021
- 2021-04-20 US US17/235,854 patent/US20210253698A1/en not_active Abandoned
-
2023
- 2023-04-14 CL CL2023001085A patent/CL2023001085A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2022105827A (ru) | Слитые конструкции антител для вовлечения nk-клеток | |
| RU2767357C2 (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| Zhang et al. | The development of bispecific antibodies and their applications in tumor immune escape | |
| Spiess et al. | Alternative molecular formats and therapeutic applications for bispecific antibodies | |
| Kontermann et al. | Bispecific antibodies | |
| KR102607909B1 (ko) | 항-cd28 조성물 | |
| JP2018525382A5 (de) | ||
| Weidle et al. | The intriguing options of multispecific antibody formats for treatment of cancer | |
| JPWO2019198051A5 (de) | ||
| Godar et al. | Therapeutic bispecific antibody formats: a patent applications review (1994-2017) | |
| RU2018108103A (ru) | КОНСТРУКЦИИ, ИМЕЮЩИЕ SIRP-α ДОМЕН ИЛИ ЕГО ВАРИАНТ | |
| CN112469477A (zh) | 与成纤维细胞活化蛋白结合的异源二聚体抗体 | |
| JP2021513961A (ja) | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 | |
| KR20210134725A (ko) | Enpp3과 cd3에 결합하는 이종이량체 항체 | |
| TW202221015A (zh) | 單一及雙靶定配體誘導之t細胞銜接體組合物 | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP7080219B2 (ja) | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 | |
| JPWO2020069133A5 (de) | ||
| Kontermann | Bispecific antibodies: developments and current perspectives | |
| WO2023164640A1 (en) | Anti-cd28 x anti-trop2 antibodies | |
| US20230383012A1 (en) | Antibodies that bind pd-l1, pd-l2, and/or cd28 | |
| CN116547306A (zh) | 抗cd28和/或抗b7h3组合物 | |
| TW202402796A (zh) | 雙功能蛋白質及其製劑和用途 | |
| RU2021137311A (ru) | ИММУНОЛОГИЧЕСКАЯ ТОЛЕРАНТНОСТЬ К MAdCAM | |
| JPWO2021170068A5 (de) |